(Q33949094)

30 July 2017

title

Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate (English)

1 reference

medroxyprogesterone acetate

30 July 2017

1 reference

1 reference

W H Utian

1

1 reference

30 July 2017

D Shoupe

2

1 reference

30 July 2017

G Bachmann

3

1 reference

30 July 2017

J V Pinkerton

4

1 reference

30 July 2017

J H Pickar

5

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

30 July 2017

published in

Fertility and Sterility

1 reference

30 July 2017

volume

75

1 reference

30 July 2017

issue

6

1 reference

30 July 2017

page(s)

1065-1079

1 reference

Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901791-5

Hot flashes: phenomenology, quality of life, and search for treatment options

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901791-5

Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901791-5

Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901791-5

Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901791-5

Can we improve compliance with long-term HRT?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901791-5

Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Esclim Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901791-5

Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901791-5

Personal perspective on low-dosage estrogen therapy for postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901791-5

Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901791-5

Initial 17beta-estradiol dose for treating vasomotor symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901791-5

Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901791-5

Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901791-5

Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901791-5

Radioimmunoassay of plasma estrogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901791-5

Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901791-5

Dose dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2801%2901791-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0015-0282(01)01791-5

1 reference

release_pulkc37gozg7tou7xbwsoj2pku

30 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pulkc37gozg7tou7xbwsoj2pku

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference